Byong Chul Yoo
Chief Science Officer & Member of Scientific Advisory BoardDr. Byong Chul Yoo, PhD, is Chief Science Officer of Liminatus Pharma, Inc. from April 30, 2025 and serves as its Member of Scientific Advisory Board. Since March 2023, Dr. Yoo has been the Chief Executive Officer of InnoBation Bio Inc. From 2019 to 2023, Dr. Yoo was the Principal Scientist at the Division of Translational Science, National Cancer Center, Republic of Korea. From 2018 to 2023, he has also been an Adjunct Professor at Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Republic of Korea. From 2013 to 2019, Dr. Yoo was a Senior Scientist at Colorectal Cancer Branch and the Biomarker Branch, Research Institute, National Cancer Center, Republic of Korea. From 2006 to 2013, he was an Associate Scientist in the Colorectal Cancer Branch. Dr. Yoo received a PhD from the University of Vienna, Vienna, Austria. He did a one year post-doctorate program at Yale University. He received his Master of Science and Bachelor of Science degrees from Sung Kyun Kwan University, Graduate School, Republic of Korea.
Positions
- Company NameLiminatus Pharma, Inc.Stock CodeLIMNPositionChief Science Officer & Member of Scientific Advisory BoardRelated Securities
